DOCSLIB.ORG

For Peer Review Only Journal: BMJ Open

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For Peer Review Only Journal: BMJ Open BMJ Open BMJ Open: first published as 10.1136/bmjopen-2015-009090 on 11 September 2015. Downloaded from Repeat infusion of autologous bone marrow cells in multiple sclerosis – protocol for a phase I extension study (SIAMMS- II) For peer review only Journal: BMJ Open Manuscript ID: bmjopen-2015-009090 Article Type: Protocol Date Submitted by the Author: 15-Jun-2015 Complete List of Authors: Rice, Claire; University of Bristol, School of Clinical Sciences Marks, David; Bristol Royal Hospital for Children, Adult BMT Unit; University of Bristol, School of Clinical Sciences Walsh, Peter; North Bristol NHS Trust, Neurosciences Kane, Nick; North Bristol NHS Trust, Neurosciences Guttridge, Martin; NHS Blood and Transplant, Redondo, Juliana; University of Bristol, School of Clinical Sciences Sarkar, Pamela; University of Bristol, School of Clinical Sciences; North Bristol NHS Trust, Neurosciences Owen, Denise; North Bristol NHS Trust, Neurosciences Wilkins, Alastair; University of Bristol, School of Clinical Sciences; North Bristol NHS Trust, Neurosciences Scolding, Neil; University of Bristol Institute of Clinical Neurosciences, Neurology http://bmjopen.bmj.com/ <b>Primary Subject Neurology Heading</b>: Secondary Subject Heading: Haematology (incl blood transfusion) Multiple sclerosis < NEUROLOGY, IMMUNOLOGY, Bone marrow Keywords: transplantation < HAEMATOLOGY on September 30, 2021 by guest. Protected copyright. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 11 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2015-009090 on 11 September 2015. Downloaded from 1 2 3 Repeat infusion of autologous bone marrow cells in multiple sclerosis – a 4 phase I extension study (SIAMMS-II) 5 6 7 8 Claire M. Rice1,2*, David I. Marks3, Peter Walsh2, Nick M. Kane2, Martin G. 9 4 1 1,2 2 1,2 10 Guttridge , Juliana Redondo , Pamela Sarkar , Denise Owen , Alastair Wilkins , 11 and Neil J. Scolding1,2 12 13 14 15 For peer review only 16 1School of Clinical 3Adult BMT Unit 4NHS Blood and 17 Sciences, Bristol Royal Hospital Transplant 18 19 University of Bristol, for Children Filton, 20 Southmead Hospital, University Hospitals North Bristol Park 21 Bristol, BS10 5NB, UK Bristol NHS Foundation Northway, Filton, 22 Trust & University of Bristol, BS34 7QH, UK 23 2Bristol Institute of Bristol, 24 Clinical Neurosciences, St Michael's Hill, 25 Southmead Hospital, Bristol, 26 Bristol, BS16 1JB, UK BS2 8BJ, UK 27 28 29 30 31 32 33 34 http://bmjopen.bmj.com/ 35 * Correspondence: [email protected] 36 37 38 39 Keywords: cell therapy 40 bone marrow 41 multiple sclerosis 42 reparative therapy on September 30, 2021 by guest. Protected copyright. 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open Page 2 of 11 BMJ Open: first published as 10.1136/bmjopen-2015-009090 on 11 September 2015. Downloaded from 1 2 3 Abstract 4 5 Introduction: The ‘Study of Intravenous Autologous Marrow in Multiple Sclerosis 6 (SIAMMS)’ trial was a safety and feasibility study which examined the effect of 7 8 intravenous infusion of autologous bone marrow without myeloablative therapy. This 9 trial was well-tolerated and improvement was noted in the global evoked potential 10 (GEP) - a neurophysiological secondary outcome measure recording speed of 11 conduction in central nervous system pathways. The efficacy of intravenous delivery 12 of autologous marrow in progressive MS will be examined in the phase II study the 13 ‘Assessment of Bone Marrow-Derived Cellular Therapy in Progressive Multiple 14 Sclerosis (ACTiMuS; NCT01815632)’. In parallel with the ‘ACTiMuS’ study, the 15 current studyFor ‘SIAMMS-II’ peer will explore review the feasibility of repeated,only non-myeloablative 16 autologous bone marrow-derived cell therapy in progressive MS. Furthermore, 17 18 information will be obtained regarding the persistence or otherwise of improvements 19 in conduction in central nervous system pathways observed in the original ‘SIAMMS’ 20 study and whether these can be reproduced or augmented by a second infusion of 21 autologous bone marrow-derived cells. 22 23 24 Methods and analysis: An open, prospective, single centre phase I extension study. 25 The 6 patients with progressive MS who participated in the ‘SIAMMS’ study will be 26 invited to undergo repeat bone marrow harvest and receive an intravenous infusion 27 28 of autologous, unfractionated bone marrow as a day-case procedure. The primary 29 outcome measure is the number of adverse events and secondary outcome 30 measures will include change in clinical rating scales of disability, global evoked 31 potential and cranial MRI. 32 33 34 Ethics and dissemination: The study has UK National Research Ethics Committee http://bmjopen.bmj.com/ 35 approval (13/SW/0255). Study results will be disseminated via peer-reviewed 36 publications and conference presentations. 37 38 39 40 Trial Registration: ClinicalTrials.gov registry NCT01932593 41 42 on September 30, 2021 by guest. Protected copyright. 43 44 Strengths and limitations of this study 45 46 47 Strengths: 48 Regulated clinical trial of cell therapy for progressive MS 49 Extension data for phase I clinical trial 50 51 Limitations: 52 Open label trial 53 Small sample size 54 55 56 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 3 of 11 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2015-009090 on 11 September 2015. Downloaded from 1 2 3 Introduction 4 5 Although effective treatments for relapsing remitting multiple sclerosis (MS) are 6 available, there are no proven therapies available to halt or reverse the progressive 7 8 phase of the disease which ultimately affects the majority of people with MS. There is 9 preclinical evidence to support a reparative role for bone marrow-derived cells in 10 demyelinating disease and, following on from this, we have begun to explore the 11 potential of autologous, unselected bone marrow cells for repair in progressive MS. 12 ‘SIAMMS’ was a safety and feasibility study of intravenous autologous bone marrow 13 (BM) infusion in patients with progressive MS 1. This study was well tolerated and 14 also raised the possibility of partial repair; conduction times in multiple central 15 nervous systemFor (CNS) peer pathways collated review as a composite onlyscore (GEP) 2 3 improved in 16 all patients studied (n=6) 1. A randomised, placebo-controlled trial will determine 17 whether autologous bone marrow infusion exerts genuine reparative effects in 18 4 19 progressive MS (‘ACTiMuS’; NCT01815632) but the purpose of ‘SIAMMS-II’ is to 20 explore whether the improvements observed in the initial study performed over 5 21 years ago have persisted and whether these can be repeated or augmented. 22 23 24 Methods and design 25 26 27 Objective and hypothesis 28 29 Our hypothesis is that intravenously-delivered autologous bone marrow cell therapy 30 in chronic MS has reparative properties. We postulate that bone marrow-derived cells 31 contribute to repair within the CNS via a multiplicity of mechanisms including 32 immunomodulation and reparative and/or neuroprotective effects. Furthering our 33 understanding of these processes will enable development and refinement of cell 34 therapy for progressive MS. http://bmjopen.bmj.com/ 35 36 37 The phase II ‘ACTiMuS’ trial will explore the efficacy of intravenous infusion of 38 autologous bone marrow-derived cell therapy in progressive MS and its laboratory 39 arm will explore the underlying mechanisms of any observed effect. ‘SIAMMS-II’ will 40 run in parallel with ‘ACTiMuS’ and will investigate whether the previously observed 41 effects can be replicated and/or augmented. 42 on September 30, 2021 by guest. Protected copyright. 43 Trial design 44 45 46 ‘SIAMMS-II’ is an open, prospective, single centre, safety and feasibility extension 47 study. The study schema is presented in figure 1. The study has UK National 48 Research Ethics Committee approval (13/SW/0255). 49 50 Sample size, eligibility & enrolment 51 52 The study is limited to the 6 people who participated in the original ‘SIAMMS’ study, 53 all of whom are under active follow up at the Bristol and Avon Multiple Sclerosis 54 (BrAMS) Unit, North Bristol NHS Trust, Bristol, UK. All participants have progressive 55 56 MS and must fulfil the inclusion and exclusion criteria as detailed in table 1. 57 58 59 60 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open Page 4 of 11 BMJ Open: first published as 10.1136/bmjopen-2015-009090 on 11 September 2015. Downloaded from 1 2 3 Trial interventions 4 5 Participants will have a bone marrow harvest and re-infusion of autologous marrow 6 as a daycase procedure. A short general anaesthesic will be given for the bone 7 marrow harvest which will be taken from the posterior iliac crests. Approximately 8 600ml marrow will be collected together with a single bone marrow trephine. The 9 10 marrow aspirate will be processed by NHSBT (filtered, bagged and labelled) prior to 11 intravenous infusion. 12 13 Assuming specific written informed consent is granted, a bone marrow trephine and a 14 small sample of the bone marrow aspirate will be retained for research. Additional 15 blood samplesFor for research peer purposes review may be requested only throughout the duration of 16 the study. 17 18 Outcome Measures 19 20 21 Primary outcome measure 22 23 The primary outcome measure is the number of adverse events (AE). For the 24 purposes of the study, an AE is defined as any unfavourable and unintended sign, 25 symptom or illness that develops or worsens during the period of the study. This is 26 irrespective of the likelihood that the AE is related to study interventions.
Load more

Recommended publications
  • Annual Report and Accounts 2019/20
    University Hospitals Bristol NHS Foundation Trust Annual Report and Accounts 2019/20 University Hospitals Bristol NHS Foundation Trust Annual Report and Accounts 2019/20 Presented to Parliament pursuant to Schedule 7, paragraph 25 (4) (a) of the National Health Service Act 2006 © 2020 University Hospitals Bristol NHS Foundation Trust 4 | University Hospitals Bristol NHS Foundation Trust | Annual Report and Accounts 2019/20 Contents 1. Chairman’s Statement ....................................................................................... 7 2. Chief Executive’s Statement ............................................................................. 9 3. Performance Report ......................................................................................... 11 3.1 Overview ........................................................................................................................... 11 3.2 Performance Analysis ....................................................................................................... 21 3.3 Finance Review ................................................................................................................ 25 4. Sustainability Report ....................................................................................... 30 4.1 Overview ........................................................................................................................... 30 4.2 Policies .............................................................................................................................
    [Show full text]
  • University Hospitals Bristol NHS Foundation Trust – 93.0% February 2013; 94.2% Year to Date
    Performance Report For the governing body of South Gloucestershire CCG, to be tabled on 24 April 2013 1 Purpose The purpose of this report is to inform the board current performance of the services commissioned by South Gloucestershire CCG against key access and quality standards. The majority of the standards in this document show performance to February 2013 i.e. month 11 of the 2013/14 financial year, with the exception of urgent care performance standards which are shown to week ending 31 March 2013. The report is intended to provide a variety of level of details. The executive summary below details the current main performance concerns of the South West Commissioning Support Unit Performance Team and is therefore provides a quick overview of current issues. There is also a scorecard attached which shows current progress against all key standards. For a more in depth commentary on performance, the sections of this report will summarise the detail of performance against key standards for: Urgent Care Planned Care Cancer Stroke/TIA Quality indicators e.g. healthcare associated infections The Governing Body is asked to note the contents of the report. Executive Summary The main current areas of concern are shown in the table below: Area Standard Current Commentary Performance Urgent 4hrs: 95% of all As at week The whole health system has been experiencing severe Care patients to be ending 31/03/13: pressure for a number of months and this has been seen, treated, maintained recently, as is demonstrated by performance admitted or 4hrs: against urgent care standards. discharged NBT: 85.76% within 4hrs of UHB: 91.48% Patient flow remains at the core of the problem, although arrival at A&E recently an increase in activity due to issues with the launch of the NHS 111 system has increased pressure Ambulance Handovers: further.
    [Show full text]
  • Mixed Sex Accommodation ‐ Number of Breaches by Month (Provider Basis)
    Mixed Sex Accommodation ‐ Number of Breaches by Month (Provider basis) December January February March April May June July August September October November December Organisation Name Primary Care Trusts Bath And North East Somerset PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Bournemouth And Poole PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Cornwall And Isles Of Scilly PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Devon PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Dorset PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Gloucestershire PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ North Somerset PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Plymouth Teaching PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Somerset PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ South Gloucestershire PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Torbay Care Trust ‐‐‐‐‐‐‐‐‐‐‐‐‐ Wiltshire PCT 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Acute Trusts Dorset County Hospital NHS Foundation Trust 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Gloucestershire Hospitals NHS Foundation Trust 112 ‐‐‐‐‐‐‐‐‐‐‐‐ Great Western Hospitals NHS Foundation Trust 63 ‐‐‐‐‐‐‐‐‐‐‐‐ North Bristol NHS Trust 538 ‐‐‐‐‐‐‐‐‐‐‐‐ Northern Devon Healthcare NHS Trust 112 ‐‐‐‐‐‐‐‐‐‐‐‐ Plymouth Hospitals NHS Trust 23 ‐‐‐‐‐‐‐‐‐‐‐‐ Poole Hospital NHS Foundation Trust ‐‐‐‐‐‐‐‐‐‐‐‐‐ Royal Cornwall Hospitals NHS Trust 81 ‐‐‐‐‐‐‐‐‐‐‐‐ Royal Devon And Exeter NHS Foundation Trust 133 ‐‐‐‐‐‐‐‐‐‐‐‐ Royal United Hospital Bath NHS Trust 0 ‐‐‐‐‐‐‐‐‐‐‐‐ Salisbury NHS Foundation Trust 67 ‐‐‐‐‐‐‐‐‐‐‐‐ South Devon Healthcare NHS Foundation Trust ‐‐‐‐‐‐‐‐‐‐‐‐‐ Taunton And Somerset NHS Trust ‐‐‐‐‐‐‐‐‐‐‐‐‐ The Royal Bournemouth And Christchurch Hospitals NHS Foundation Trust 0 ‐‐‐‐‐‐‐‐‐‐‐‐ The Royal National Hospital For Rheumatic Diseases NHS Foundation Trust 0 ‐‐‐‐‐‐‐‐‐‐‐‐ University Hospitals Bristol NHS Foundation Trust 29 ‐‐‐‐‐‐‐‐‐‐‐‐
    [Show full text]
  • North Bristol NHS Trust Quality Account 2020/21
    North Bristol NHS Trust Quality Account 2020/21 Exceptional healthcare, personally delivered Contents 04 Part 1: A statement on quality from the chief executive 08 Part 2: Priorities for improvement and statements of assurance from the board 2.1 Priorities for improvement: 09 Priority one: Ensure quality and safety of services is sustained whilst recovering from the impact of the COVID-19 pandemic; including: • Maintaining excellence in infection prevention and control • Ensuring the appropriate clinical priorities for recovery work • Keeping people waiting for planned care safe • Maintaining safety and excellent outcomes from emergency care 11 Priority two: Being outstanding for Safety—a national leader in implementing the NHS Patient Safety Strategy 13 Priority three: Ensuring excellence in our maternity services, delivering safe and effective maternity care 15 Priority four: Meeting the identified needs of patients with learning difficulties, autism, or both 2.2 Statements from the board 17 Review of services 19 Care Quality Commission 21 Research and Innovation 22 Operational Performance 27 Hospital Episode Statistics and DQIPs 28 Clinical Coding Performance 29 Clinical Coding Improvement Strategy 30 Data Security & Protection Toolkit 32 Part 3: Our quality indicators 3.1 Patient Safety 32 Patient Safety Indicators 33 Freedom to Speak Up 34 Guardian for safe working hours 35 Quality Indicators 37 Safeguarding Adults 38 Safeguarding Children 3.2 Clinical Effectiveness 39 Getting It Right First Time (GIRFT) - specialty outcomes 40 Mortality
    [Show full text]
  • University Hospitals Bristol NHS Foundation Trust Annual Report
    University Hospitals Bristol NHS Foundation Trust Annual Report and Accounts 2010 – 2011 University Hospitals Bristol NHS Foundation Trust Annual Report and Accounts 2010 – 2011 Presented to Parliament pursuant to Schedule 7, paragraph 25(4) of the National Health Service Act 2006 Table of Contents 1. Chairman’s Statement ................................................................................................... 1 2. Chief Executive’s Foreword ........................................................................................... 3 Introduction........................................................................................................................ 3 Histopathology Inquiry ....................................................................................................... 3 Clinical services ................................................................................................................. 3 Research and innovation ................................................................................................... 4 Teaching and learning ....................................................................................................... 5 Board of Directors.............................................................................................................. 5 Looking forward ................................................................................................................. 6 3. Directors’ Report ...........................................................................................................
    [Show full text]
  • Bristol Mayor, Marvin Rees, Opens BASF Wellbeing Day 2016
    Winter 2016-17 INSIDE: BASF NEWSLETTER Page 2 - Occupational Bristol Mayor, Therapy students experience life with BASF Marvin Rees, opens BASF Wellbeing Day 2016 BASF was hugely grateful to Mayor of Bristol, Marvin Rees, for opening our Wellbeing Day on 30th September 2016. He introduced the day with a brilliant personal account of the impact of stroke. As a young community worker, he supported an Page 10 - Fundraisers of individual on his journey to life after stroke. He supported him the Year raise awareness about stroke through supporting his personal challenge of climbing up PenYFan, attracting much media attention. Marvin Rees noted that it was not just the physical impact of stroke that people needed support with but also the emotional impact, and that families and carers also need support and the voluntary sector plays a key role in this. Page 12 - Service user to volunteer – Len Osgood’s stroke story BRISTOL AREA STROKE FOUNDATION The Gatehouse Centre, Hareclive Road, Hartcliffe, Bristol, BS13 9JN T: 0117 964 7657 Left to right: BASF Operations Manager, Rebecca Sheehy; [email protected] Bristol Mayor, Marvin Rees; Dr. Philip Clatworthy Consultant www.basf.uk.com Stroke neurologist at North Bristol NHS Trust; Dr Praveen Kumar, Charity number 287554 Senior Lecturer in Physiotherapy, University of West of England. continued on page 6 ➤ SUPPORTING PEOPLE AFFECTED BY STROKE continued on page 2 ➤ Dates for your diary 2017 ACTion After Stroke (4/5 weeks) Bristol Stroke Café Date: Tuesday 21st February – Tuesday 21st March Monthly, every
    [Show full text]
  • CQC Evidence Appendix
    North Bristol NHS Trust Evidence appendix North Bristol NHS Trust Date of inspection visit: Southmead Hospital 8 Nov to 29 Nov 2017 Southmead Road Bristol BS10 5NB Date of publication: 6 March 2018 Tel: 0117 950 5050 www.nbt.nhs.uk This evidence appendix provides the supporting evidence that enabled us to come to our judgements of the quality of service provided by this trust. It is based on a combination of information provided to us by the trust, nationally available data, what we found when we inspected, and information given to us from patients, the public and other organisations. For a summary of our inspection findings, see the inspection report for this trust. Facts and data about this trust Details of sites and locations registered with CQC Three locations are registered with the Care Quality Commission. Southmead Hospital Cossham Hospital Frenchay Hospital We only inspected Southmead Hospital as part of this inspection. Background to the trust North Bristol NHS Trust is an acute trust located in Bristol that provides acute hospital and some community services to a population of about 900,000 people in Bristol, South Gloucestershire and North Somerset. The trust is not a foundation trust. It also provides specialist services such as neurosciences, renal, trauma and plastics/burns to people from across the South West and in some instances nationally or internationally. The new hospital at Southmead opened in May 2014 when the main hospital at Frenchay closed. Southmead Hospital provides a full range of acute clinical services. The trust also provides community healthcare for children and young people.
    [Show full text]
  • North Bristol NHS Trust Strategy 2016-2021
    North Bristol NHS Trust Strategy 2016-2021 Contents 1 Executive summary 04 2 Introduction 06 3 Our values and vision 08 4 Strategic themes 10 5 Next steps and delivery plan 20 6 Conclusion 22 7 Appendix A: North Bristol NHS Trust today 24 8 Appendix B: The challenges we face 30 1 | Executive summary North Bristol NHS Trust Achieving our vision to provide This strategy has been the high quality care that we developed for the period 2016 - is a provider of local aspire to within the resources 2021 to provide focus and clarity hospital services and available is an increasing of direction for our organisation complex specialist care challenge. By improving patient and its stakeholders. It takes flow, maximising productivity, into account detailed analysis for a large population using resources including our of the Trust, activity, quality, in the South West of workforce wisely, and sharing performance, outcomes, England. Employing over best practice across the Trust, opportunities and challenges, our finances will be sustainable and is informed by clinician, 8,000 highly skilled and and we will meet the national staff and patient views. caring staff, we aim to standards for operational The detail of this analysis is performance in the coming described in appendices A & B: deliver excellent clinical years. The aims described in The eight strategic themes that outcomes and a great this strategy are designed to will form the basis of our plans create an organisation in which experience for all service over the next five years are: the necessary savings and users: exceptional efficiencies are delivered to 1) Change how we deliver healthcare, personally enable us to do more with the services to generate delivered.
    [Show full text]
  • 1 Reference: FOI 27719 BNSSG 15C Subject: Facial Nerve Palsy I Can
    Reference: FOI 27719 BNSSG 15C Subject: Facial Nerve Palsy I can confirm that the CCG does hold some of the information requested; please see responses below: QUESTION RESPONSE Bristol, North Somerset and South Gloucestershire CCG does not hold this 1. Of those with facial nerve palsy who have information. The provider trusts may be able to not made a full or nearly full recovery at provide this information. If you would like to 12 weeks following onset, can you redirect your Freedom of information request provide an estimate of the percentage of please follow the links. such patients who are referred for rehabilitation of persistent facial University Hospitals Bristol NHS Foundation pain/discomfort and dysfunction? Trust North Bristol NHS Trust Persistent facial nerve palsy – most common presentation (outside of surgical complication, in which case referral would come from the surgical team, not primary care) – the CCG would follow the National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries (CKS) as below: Refer urgently to neurology or to ear, nose, and throat (ENT) if there is: o Any doubt regarding the diagnosis. o Recurrent Bell's palsy. 2. If a patient with facial nerve palsy is o Bilateral Bell's palsy. routinely referred to secondary care for If the cornea remains exposed after rehabilitation therapy, which hospital(s) attempting to close the eyelid, refer urgently and department(s) do you refer to? to ophthalmology. If the paralysis shows no sign of improvement after 1 month, or there is suspicion of a serious underlying diagnosis (for example, cholesteatoma, parotid tumour, malignant otitis externa), refer urgently to ENT.
    [Show full text]
  • Choosing Your Hospital, Contact: Choosing Your Hospital
    hospital North Somerset Primary Care Trust your Choosing PHOTOGRAPHY COPYRIGHT: ALAMY, GETTY, JOHN BIRDSALL, NHS LIBRARY, REX, SPL, ZEFA/CORBIS copy of this booklet is also Crown copyright 2005. available on: www.nhs.uk A Tel: 01454 883655 BS37 4AF Bristol Yate 248 Station Road Chipping Sodbury Memorial Day Centre Referral Management Centre Patient Choice Coordinator For more help with choosing your hospital, contact: © 270744/151 What is patient choice? Things to think about If you and your GP decide that you need to see a specialist Where can I go for treatment? for further treatment, you can now choose where to have You might already have experience of a particular hospital or know someone who has. Now you can choose – where would you like to go? Or, if you like, your treatment from a list of hospitals or clinics. From April, your GP can recommend a hospital where you can be treated. you may have an even bigger choice – full details will be How do I find out more information on the NHS website (www.nhs.uk). about my condition? Your GP should be able to give you the answers to some of the questions This guide explains more about how the process works. you have. Or contact NHS Direct: visit www.nhsdirect.nhs.uk or call It also gives you answers to some questions you may have. 0845 4647 and ask to speak to a health information advisor. Plus, there are details of the hospitals you can choose and How long will it take? some information to help you choose the one that will be How quickly do you want to be treated? Would you be willing to travel best for you.
    [Show full text]
  • North Bristol NHS Trust Job Description
    North Bristol NHS Trust Exceptional healthcare, personally delivered Job Description SECTION 1 – JOB DETAILS Job Title: Consultant Histopathologist Division: Core Clinical Services Location/Base: Southmead Hospital, Bristol SECTION 2 – THE WORK OF THE DEPARTMENT North Bristol NHS Trust is seeking a full-time (10 PAs) substantive Consultant Histopathologist within the Department of Cellular Pathology. This is a replacement post. It is expected that the appointee will have an established or developing interest in Gastrointestinal (GI) Pathology and will join a team of 3 specialists and 4 non-care GI Pathologists. As we are growing our service across all sub-specialisms, additional interest in Head and Neck Pathology and Endocrine Pathology is highly desirable. Severn Pathology Severn Pathology lies at the heart of patient care. Severn Pathology’s mission is to provide a best in class, high quality, innovative, value for money Pathology service that serves the needs of the healthcare market in the South West region and beyond. In doing so, we will strive to put Pathology at the heart of a modern patient pathway, serving an increasingly diverse market. The combination of general pathology services with a thriving and growing genetics laboratory service will ensure continued development of state of the art pathology services in to the future. On 1 May 2016, North Bristol NHS Trust’s (NBT) Department of Cellular Pathology and the Department of Histopathology at the University Hospitals Bristol NHS Foundation Trust (UHB) merged and co-located the bulk on their services to a new, purpose-built facility on the Southmead Hospital site. The service is managed by NBT which also manages the Essential Services Laboratory and Paediatric / Perinatal mortuary located on UHB premises.
    [Show full text]
  • 2025 Embracing Change, Proud to Care
    1 2 Contents Foreword 4 Introduction – Refreshing our strategy 6 Section one - Our strategic context 8 Who we are 8 Where we are in 2019 – Our case for change 13 Summary – What we need to focus on for 2025 23 Section two - Our strategy for 2025 25 Our mission, vision and values 25 Our strategic priorities 26 Our strategic choices 27 Our strategic priorities and objectives 29 Section three - Implementing our strategy 32 Specialist and regional services 33 Local acute services and integrated care 36 Education and workforce 39 Research and innovation 42 Section four - Our enabling strategies 46 Our integrated strategy framework 46 Our people strategy 46 Our quality strategy 47 Our digital strategy 48 Our improvement and innovation strategy 48 Our finance strategy 49 Our estate strategy 50 Our communications strategy 50 Section five - Governance, assurance and communication 51 3 Foreword A strategy is only as good as the leadership commitment and financial resources that go into making it happen. University Hospitals Bristol NHS Foundation Trust (UH Bristol) has a solid track record over the last decade of setting ambitious strategic plans and delivering them. We have invested over £200million in new or expanded hospital facilities, most noticeably in the Bristol Heart Institute, Bristol Royal Infirmary, Bristol Royal Hospital for Children and the Bristol Haematology and Oncology Centre. We have grown and enhanced our range of specialist services for the people of the South West, South Wales and further afield. We are one of only a few acute hospital Trusts nationwide to have been awarded an Outstanding rating from the Care Quality Commission and we have achieved Global Digital Exemplar status for our work to transform healthcare through better use of information technology.
    [Show full text]